October 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Hair loss significantly affects emotional and social well-being.
October 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Hair loss significantly affects emotional and social well-being.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
August 2025 in “Medical Journal of Armed Police Force Nepal” Alopecia areata is more common in males, mostly affects the scalp, and often appears as patchy hair loss.
July 2025 in “JAAD Case Reports” A thorough assessment and combined treatment are crucial for managing complex alopecia, especially in patients with skin of color.
July 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Higher stress levels may worsen alopecia areata, suggesting stress management is important for treatment.
June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
June 2025 in “British Journal of Dermatology” Patients with alopecia areata in the UK face barriers to care, needing better-defined pathways and more education for general practitioners.
April 2025 in “International Journal of Dermatology” JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.
February 2025 in “Indian Dermatology Online Journal” Calcipotriol is the safest and most effective for hair regrowth in localized alopecia areata.
January 2025 in “Dermatologic Therapy” Baricitinib effectively promotes hair regrowth in alopecia areata patients with mild side effects.
January 2025 in “SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital” PRP injections are safe and effective for alopecia areata, but steroids are still the preferred treatment.
January 2025 in “Journal of Rawalpindi Medical College” Alopecia Areata affects both genders almost equally, mostly on the scalp, with common signs like yellow dots and exclamation mark hairs, especially in young people.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Patients with anxiety or depression report more severe alopecia areata.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
November 2024 in “Skin Appendage Disorders” Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
October 2024 in “La Tunisie Médicale” Over half of alopecia areata patients in Tunisia experience depression, highlighting the need for psychological support.
September 2024 in “JEADV Clinical Practice” Alopecia areata significantly affects patients' lives, causing physical, psychological, social, and financial challenges.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
May 2024 in “JEADV Clinical Practice” A change in SALT scores of 42 or 43 indicates meaningful improvement in alopecia areata treatment.
March 2024 in “Clinical, cosmetic and investigational dermatology” Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.
January 2024 in “Pharmacoepidemiology” Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
January 2024 in “JEADV clinical practice” Patients were highly satisfied with shared medical appointments for hair loss treatment.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
January 2024 in “Annals of Dermatology” Current treatments for Alopecia Areata don't fully meet patients' needs, indicating a need for better therapies.
Combining baricitinib with golimumab helped regrow hair in a patient with ankylosing spondylitis and alopecia areata.
January 2024 in “Annals of Dermatology” DPCP immunotherapy is effective for alopecia areata, and understanding influencing factors can improve treatment and satisfaction.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
Reducing the dose of Baricitinib to 2mg still helped over half of the patients with severe scalp alopecia maintain their hair regrowth after two years.